INTRODUCTION
The discovery of the lipocortins, identified by their being inhibitors of phospholipase A # (PLA # ) [1, 2] , provided some of the first structural and functional information that led to the identification of a large group of proteins now known as the annexins [3] . Both annexins and phospholipases A # are characterized by their ability to bind to phospholipid interfaces as the presumed first step in their biological action. The annexins have an absolute requirement for Ca# + for this interfacial binding, whereas the two most well-defined classes of PLA # , the 14 kDa secretory PLA # and the 85 kDa cytosolic PLA # (cPLA # ) also have a requirement for Ca# + to allow overall function. In the case of cPLA # , Ca# + is not required for catalysis but is normally required for binding to biological membranes. This requirement is associated with an N-terminal Ca# + -dependent phospholipidbinding domain (CaLB) that is similar to several other proteins involved in signal transduction [4, 5] . Ca# + concentrations in the micromolar range promote translocation to membranes and are correlated with Ca# + concentrations required in itro for catalytic activity. Thus intracellular Ca# + concentration, together with enzyme phosphorylation [4, 5] , is believed to have a crucial role in determining the catalytic activity of cPLA # within the cell and, in particular, the release of arachidonic acid. Therefore a complete understanding of factors within the cell that might regulate cPLA # activity is of considerable importance for many aspects of cell regulation.
The annexins show a marked preference for binding to interfaces, bilayers or vesicles containing anionic lipids, whereas for annexin V a specific receptor site for phosphatidylserine has been proposed [6] . No significant binding of annexins to pure phosphatidylcholine can be observed except possibly at very high Abbreviations used : CaLB, Ca 2 + -dependent phospholipid-binding domain ; (c)PLA 2 , (cytosolic) phospholipase A 2 ; DOPG, dioleoyl phosphatidylglycerol ; SAPA, 1-stearoyl 2-arachidonyl phosphatidic acid ; SAPC, 1-stearoyl 2-arachidonyl phosphatidylcholine ; SUV, small unilamellar vesicle. 1 To whom correspondence should be addressed.
V over a range of Ca# + concentrations (1 µM-2.5 mM), a result that presumably reflects the zwitterionic nature of the phospholipid and the known inability of annexins to bind to such interfaces. In contrast, the hydrolysis of dioleoyl phosphatidylglycerol, which is an effective anionic phospholipid substrate for this enzyme, and more significantly that of 1-stearoyl 2-arachidonyl phosphatidic acid, were readily inhibited by annexin V, although these effects were Ca# + -dependent. The Ca# + concentrations required for inhibition in the assay system in itro are greater than those associated with Ca# + -stimulated events within the cell, suggesting that a role for annexin V in regulating cPLA # activity might not involve a substrate depletion mechanism in i o unless factors in addition to Ca# + and phospholipids contribute to the binding of annexin V to cell membranes.
Ca# + concentrations [7] [8] [9] . Although cPLA # does not have an absolute specificity for a particular class of phospholipid and most studies in itro have been performed with 1-stearoyl 2-arachidonyl phosphatidylcholine (SAPC) or 1-palmitoyl 2-arachidonyl phosphatidylcholine, the substrate in i o for this enzyme remains to be established clearly and therefore whether annexins could have a role in modulating enzyme activity by a substrate depletion mechanism. Annexin V has a high intracellular concentration, where it can form up to 2 % of total cell protein in certain tissues [10] . Therefore, considering that both annexin V and cPLA # are found within the cytosol and have both been demonstrated to translocate to the nuclear membrane on increases in intracellular Ca# + levels [11] [12] [13] , it is of importance to investigate mechanisms by which annexin V could modulate cPLA # catalytic activity and, in particular, whether a substrate depletion mechanism could operate successfully in the cell.
In this study we have investigated the ability of human recombinant annexin V to inhibit human cPLA # in itro by using a variety of substrates and monitoring cPLA # activity with a continuous fluorescence displacement assay.
EXPERIMENTAL
Dioleoyl phosphatidylglycerol (DOPG), 1-stearoyl 2-arachidonyl phosphatidic acid (SAPA), arachidonic acid and oleic acid were obtained from Sigma. SAPC was purchased from Avanti Polar Lipids (Alabaster, AL, U.S.A.). The purity of all lipids was confirmed by TLC. 11-Dansylaminoundecanoic acid was obtained from Molecular Probes (Eugene, OR, U.S.A.). Recombinant human cPLA # , which was a gift from Zeneca Pharmaceuticals (Macclesfield, Cheshire, U.K.), was purified as described previously [14] . Recombinant human annexin V was a gift from Dr. J. Romisch (Behring Institutes, Marburg, Germany). Nterminal sequencing confirmed that the recombinant annexin V, in contrast with the native protein, has an unblocked N-terminal alanine residue ; however, comparisons between the two proteins have given identical results [15] . Fatty acid-binding protein was prepared as previously described [16] . The purity of all proteins was confirmed by SDS\PAGE.
PLA 2 /annexin V assays
A continuous assay of fluorescence displacement, which has been described previously [17] , was used to monitor cPLA # and annexin V activity. Assays were performed in a 1 ml volume in plastic cuvettes containing 0.1 M Tris\HCl, pH 8.0, 0.1 M NaCl, CaCl # (for concentrations see the legends to the Figures), 1 mM EGTA, 11-dansylaminoundecanoic acid (1 µM), fatty acid-binding protein (approx. 12 µg) and phospholipid substrate (generally 2.5 nmol\ml) in the form of small unilamellar vesicles (SUVs). Phospholipid was added to the assay cocktail either by rapid injection of a phospholipid stock solution in methanol or as a suspension in assay buffer that had been subjected to probe sonication. This solution was excited at 350 nm and the fluorescence was measured at 500 nm with a Hitachi F2000 fluorimeter ; data were recorded on a computer. Annexin V was added to the assay and left for 1 min before the addition of PLA # and the measurement of fluorescence displacement. Enzyme rates in the presence of annexin V were compared with rates from the standard assay containing enzyme only. Calibration of fluorescence displacement was performed with 0.2 mM arachidonic acid (SAPC, SAPA) or 0.2 mM oleic acid (DOPG).
RESULTS

Annexin V inhibits the cPLA 2 -catalysed hydrolysis of DOPG but not SAPC
The kinetics of SAPC hydrolysis by cPLA # is unusual in that when using SUVs prepared by liposome sonication or by solvent injection a burst phase of hydrolysis is observed that rapidly
Figure 1 Effect of annexin V on SAPC and DOPG hydrolysis by cPLA 2
The inhibition of cPLA 2 by annexin V was determined with SAPC or DOPG (2.5 nmol/ml) as substrate in the form of SUVs, and 2.5 mM Ca 2 + . PLA 2 activity in the presence of annexin V was determined and is expressed as a percentage of the activity in the absence of annexin V. Assays were performed with 1 µg of enzyme. Symbols : , DOPG ; >, SAPC. Values are meanspS.D., n l 3.
decreases to a slow second phase. This burst phase seems to result from enzyme molecules being trapped on vesicles during hydrolysis [14, 18] . We have argued that this trapping of enzyme molecules on the vesicles is of a co-operative nature and that the burst of hydrolysis reflects the hydrolysis of the outer surface of these vesicles [14] . It would be expected that the hydrolysis of SAPC by cPLA # would be only minimally inhibited in the presence of annexin V by a mechanism involving interfacial competition and sequestration because of the low affinity of annexin V for phosphatidylcholine interfaces.
The results of performing such an assay in the presence of 2.5 mM free Ca# + are shown in Figure 1 and clearly demonstrate the inability of annexin V to inhibit cPLA # under the conditions used here. However, we have observed that cPLA # is also able to hydrolyse the anionic phospholipid DOPG at a significant rate, being approx. 15 % of that seen with SAPC under these assay conditions. It would be expected that the hydrolysis of such an anionic substrate would be inhibited by annexin V : this is clearly seen in Figure 1 . This inhibition, which is achieved with a limited substrate concentration (2.5 nmol) at 2.5 mM Ca# + , is halfmaximal at approx. 1 µg (28 pmol) of annexin V. Moreover, the stoichiometry of the inhibition curve suggests a substrate depletion mechanism involving a coating of the phospholipid vesicle surface by annexin V. Thus it would be expected that one annexin V molecule would cover approx. 30-60 molecules of phospholipid [7, [19] [20] [21] and hence 2.5 nmol of phospholipid (which should equate to at least 1.25 nmol of the phospholipid in the outer monolayer of the SUV) would require between 42 and 84 pmol (1.5-3 µg) of annexin V. The results shown in Figure 1 are clearly consistent with this stoichiometric relationship. The lack of inhibition seen when identical assays were performed with excess substrate (50 µg\ml) is consistent with this mechanism of substrate depletion (results not shown).
Dependence of the ability of annexin V to inhibit cPLA 2 activity on Ca 2 + concentration
In view of the low micromolar levels of Ca# + found within the cell, it was important to study the relationship between Ca# + and the effect of annexin V on cPLA # . Rates of hydrolysis of SAPC vesicles increased significantly when Ca# + levels were increased from micromolar to millimolar levels ( Figure 2, upper panel) , a result in line with assays reported previously with this substrate with the use of radiometric assays [22] . In contrast, the activity of cPLA # on SAPC SUVs was not affected to any significant extent by annexin V (10 µg) over the range of Ca# + concentrations used (Figure 2, upper panel) . Once again this is expected because of the inability of the annexin to bind to a zwitterionic phospholipid.
The ability of annexin V to inhibit cPLA # activity and the requirement for Ca# + is demonstrated in Figure 2 (lower panel), with DOPG as the phospholipid substrate. Annexin V (2 µg) completely inhibited cPLA # activity at 2.5 mM Ca# + but this effect was diminished as free Ca# + levels were lowered ; at 100 µM Ca# + , 2 µg of annexin V had no inhibitory action on the enzyme. This result must reflect the dependence of annexin V on Ca# + concentration for binding to DOPG and thus its ability to sequester phospholipid substrate effectively from the enzyme.
Hydrolysis of SAPA by cPLA 2 is inhibited by annexin V in the presence of micromolar levels of Ca 2 +
Although we have been able to demonstrate, by using DOPG, the principle of cPLA # inhibition by substrate depletion, this is not of obvious physiological relevance, because phosphatidylglycerol is not a widely distributed phospholipid in eukaryotic cells. However, SAPA can be generated within a biological membrane by the action of phospholipase D on the phosphatidylcholine substrate SAPC. As can be seen in Figure 3 , annexin V decreases the activity of cPLA # on SUVs composed of SAPA at 100 µM Ca# + . Again, this inhibition is Ca# + -dependent ; at 20 µM Ca# + , up to 10 µg of annexin V has no significant effect on the enzyme. It should be noted that it was not possible to use Ca# + concentrations above 100 µM with this phospholipid owing to a rapid decline in enzyme activity in this assay, presumably owing to vesicle aggregation.
Phosphatidic acid is one of several anionic phospholipids that have been reported to activate the hydrolysis of radioactive SAPC by cPLA # ; this activation was most marked by PtdIns(4,5)P # [23] . We observe a similar activation of SAPC hydrolysis by 2 % (mol\mol) PtdIns(4,5)P # but such enhanced hydrolysis was not inhibited by annexin V even in the presence of 2.5 mM Ca# + (results not shown).
DISCUSSION
Since the original discovery of annexin 1 (lipocortin 1) [1, 2] as a potential mediator of the inflammatory effects of glucocorticoids, there has been considerable interest in Ca# + and phospholipidbinding proteins as inhibitors of PLA # . The early concept that these proteins caused inhibition by a direct interaction with PLA # (secretory PLA # at that time) has been replaced to a large extent by a substrate depletion model in which inhibition could be reversed by the presence of excess substrate. Although such a model might lack the immediate attraction of a mechanism involving the direct inhibition of the enzyme by annexin, the high concentration of annexin V in cells [10] , coupled with its capacity to aggregate on low curvature surfaces [7, 24] , still offers a potentially effective mechanism for PLA # modulation within the cell by denying the enzyme access to crucial membrane domains.
In the present study we have taken advantage of a fluorescence displacement assay that allows the hydrolysis of low concentrations of a variety of phospholipid vesicles by PLA # to be monitored in terms of total fatty acids released. This method allows sufficient annexin V to be added to coat the interfacial surface completely and enabled the assay of human cPLA # activity with a variety of phospholipid substrates, some of which are not available as radioactive substrates.
The results have clearly established that under the assay conditions used in itro, annexin V was unable to inhibit the hydrolysis of SAPC over a range of Ca# + concentrations (1 µM-2.5 mM) as would be anticipated from the known inability of annexin V to bind to zwitterionic interfaces. The fact that no inhibition could be seen with annexin V at low concentrations of Ca# + is of interest because Kim et al. [25] showed cPLA # inhibition by annexin I at low Ca# + concentrations, which they proposed was by a specific interaction between annexin I and cPLA # . A mechanism involving specific interaction between the annexin and cPLA # finds indirect support from other reported properties of the annexins. For example, cPLA # has a CaLB domain, a feature in common with conventional forms of protein kinase C (PKC) and such PKCs are reported to be inhibited by annexin V [26] ; however, the molecular mechanism of this inhibition of PKC remains obscure. It is of interest that recently a direct interaction between P120 GAP and annexin VI has been reported involving this CaLB domain [27] . The fact that cPLA # also has a CaLB domain provides a possible mechanism for direct modulation of this PLA # by annexins. In contrast with negative results with SAPC, when an anionic substrate (DOPG) was used, prior addition of annexin V resulted in inhibition, whereas the stoichiometry of this inhibition was consistent with the normal substrate depletion mechanism. No inhibition was seen when the assays were performed in the presence of excess DOPG relative to added annexin V. The effect of Ca# + concentration on the inhibitory effect of annexin V was of particular interest. The results clearly established that under these assay conditions high cPLA # activity could be sustained by micromolar concentrations of Ca# + , whereas annexin V inhibition by substrate depletion required Ca# + concentrations in excess of 100 µM. A similar phenomenon was seen when SAPA, which could be generated from SAPC in the cell by the action of phospholipase D, was used as substrate. Again, cPLA # activity was inhibited by annexin V, but now at 100 µM Ca# + , whereas no significant inhibition was seen at 20 µM Ca# + .
Recent work demonstrates that, on activation, cPLA # translocates to the nuclear envelope, where binding to specific regions must occur [11, 12] . It is of interest that it has now been shown that annexin V also translocates to this nuclear envelope on cell activation [13] and hence a modulatory role of this annexin on cPLA # cannot be discounted. At present the precise molecular species of phospholipid in the nuclear envelope that is hydrolysed by cPLA # is not known [28] . The identification of this species and the possible modulation of its availability for hydrolysis by annexin V is of obvious importance, particularly as part of the inflammatory response of appropriate cells. However, if annexin V were to have a role in modulating cPLA # activity, the results described would seem to rule out a mechanism simply involving substrate sequestration.
A modulatory role for annexin V in the cell could, however, involve an interaction with a specific membrane-associated protein in addition to binding to the phospholipid interface. Such proteins have already been proposed to explain the interaction of annexin with cell membranes at low Ca# + concentrations [29] and might provide an explanation for the ability of annexin V to inhibit cPLA # activity in permeabilized HL-60 cells [30] .
In summary, the ability of annexin V to inhibit cPLA # can be clearly demonstrated in itro when using anionic phospholipid substrates in a mechanism involving substrate sequestration. However, the Ca# + sensitivity of this process seems to rule out the possibility of such a simple mechanism operating in i o despite the high concentrations of annexin V found in some tissues.
